12th Annual Yale Epilepsy Symposium

Friday, June 2, 2023, 7:00 AM - 4:30 PM, Yale West Campus, Orange, CT

Epilepsy and seizures effect almost 3 million Americans of all ages. Tremendous advances have been made in the treatment of epilepsy over the past decade with drug therapy, surgery, neurostimulation, and ketogenic diets. The wide range of antiepileptic drugs (AEDs) remains the cornerstone of treatment. Even with the plethora of epilepsy therapies now available, the Center for Disease Control and Prevention estimates that at least 45% of people with epilepsy continue to experience seizures because there’s a serious gap that exists between established recommendations and the actual care patients receive.

This one-day symposium will bring participants up to date on new advancements in the field of epilepsy and increase their awareness of new therapies available for their patients.

Case studies will be presented with opportunities for questions at the end of each topic.

Target Audience: Attendings, Physicians, Radiologists, Neurosurgeons, Neurologists, Neurophysiology Techs, Fellows, Medical Students, Nurses, PAs

The program will offer 7.5 AMA PRA Category 1 Credits™.

1. Review new anti-epileptic medications
2. Discuss updates of rescue seizure therapies
3. Apply the most recent imaging techniques in patients with epilepsy
4. Describe the ketogenic diet and its usefulness in treating both pediatric and adult patients with medically refractory epilepsy
5. Clarify the laws and regulations in Connecticut and surrounding states for driving with a diagnosis of epilepsy
6. Develop plans for rescue therapy in treatment of seizure clusters and prolonged seizures. Understand translating these plans in to written seizure action plans.
7. Discuss the role of the neurologist in the treatment of psychogenic non-epileptic attacks (PNEA)
8. Examine the role of using multimodality monitoring in patients suffering from status epilepticus
9. Identify the potential roles of involving advanced practice providers (PAs, APRNs) in an epilepsy practice.
10. Explain the current treatment paradigms for patients suffering from post acute symptomatic seizures
11. Explain the role of the neuropsychologist in the evaluation of an epilepsy patient and updates to the care they can offer
12. Identify patients who might be good candidates for a clinical trial for epilepsy
13. Discuss surgical treatment options for patients with epilepsy, including neurostimulation
14. Develop an approach for diagnosing and treating patients with likely autoimmune epilepsy disorders
15. Discuss options for seizure safety, including the use of wearable devices and alarms.

Registration Fees
Registration fee* includes continental breakfast, refreshment breaks, and lunch:

• Physician- $150
• Nurse/PA/Allied Health Professional- $75
• Non-Yale Resident/Fellow/Student†- $30
• Yale Resident/Fellow/Student†- Complimentary

• Comprehensive Epilepsy Center Nurses - complimentary
• Comprehensive Epilepsy Center Staff- complimentary

Online registration will close the morning before the program.

†A letter of verification from department head must accompany registration. A pdf copy of the letter should be sent separately to Yale CME at [email protected]. Please include program name in subject field. 
*All cancellations must be received in writing (or via e-mail) at least one week prior to the start of the conference to receive a refund. Any requests for refunds received after this date, or by telephone, will not be honored.

If paying via check, include conference name in the memo, make check payable to Yale University and send to:
Center for Medical Education
c/o Allison Rentfro
367 Cedar Street – ESH Building A – 2nd floor
New Haven, CT 06510

Accreditation Statement
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Designation Statement
The Yale School of Medicine designates this educational activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
It is the policy of Yale School of Medicine, Continuing Medical Education (CME), to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All individuals involved in the development and presentation of Accredited Continuing Education activities are required to disclose all financial relationship(s) with ineligible companies (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) that has occurred within the past 24 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. This information is disclosed to all activity participants prior to the commencement of the educational activity.

Mitigation of Financial Relationships Statement
Yale CME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible companies. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Financial Statement
The Yale School of Medicine, Department of Neurology is grateful to its supporters.  They are acknowledged in all conference materials.

AMA PRA Category 1 Credits™ (7.50 hours), Non-Physician Attendance (7.50 hours)

The registration form for this activity is currently unavailable.

Mitigation of Relevant Financial Relationships

Yale Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Friday, June 2, 2023